Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating activities:
Net loss	$ (1,915,327)	$ (1,046,109)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization and depreciation	1,588	1,785
Non-cash lease expense	29,265	26,936
Share-based compensation	59,961	73,634
Change in fair value of convertible debt	(165,382)
Amortization of deferred issuance costs associated with convertible debt		10,242
Change in operating assets and liabilities:
Contracts and grants receivable	54,225	(102,878)
Prepaid expenses and other current assets	414,138	60,894
Research and development incentives receivable	17,379	98,456
Operating lease liability	(29,359)	(26,256)
Accounts payable and accrued expenses	391,929	(970,757)
Accrued compensation	(200,899)	(292,200)
Net cash used in operating activities	(1,342,482)	(2,166,253)
Financing activities:
Proceeds from issuance of common stock pursuant to B. Riley At Market Issuance Sales Agreement		70,730
Convertible debt repayments		(1,000,000)
Net cash used in financing activities	(8,992)	(931,558)
Effect of exchange rate on cash and cash equivalents	(3,136)	4,046
Net decrease in cash and cash equivalents	(1,354,610)	(3,093,765)
Cash and cash equivalents at beginning of period	8,446,158	13,359,615
Cash and cash equivalents at end of period	7,091,548	10,265,850
Supplemental information:
Cash paid for state income taxes	17,965	2,110
Cash paid for interest	64,047	213,490
Cash paid for lease liabilities:
Operating lease	34,100	33,325
Non-cash investing and financing activities:
Pontifax conversion of portion of debt principal into common stock	99,416
Deferred issuance cost reclassified to additional paid-in capital		53
Redemption liability for Series D preferred stock		43
Public offering costs included in accounts payable	123,689
B. Riley Sales Agreement
Financing activities:
Stock issuance costs associated		$ (2,288)
Public Offering
Financing activities:
Stock issuance costs associated	$ (8,992)